“The present circumstance has uncovered some structural weaknesses while in the EU’s medicines source chain along with a large dependence on non-EU international locations for active pharmaceutical ingredients,” Kyriakides said. She suggested that offer chain challenges be tackled within an EU pharmaceutical strategy expected to get introduce